Vimpat (lacosamide) Now Approved by FDA for Primary Generalized Tonic-Clonic Seizures and Expanded Pediatric Use for People Living with Epilepsy

Vimpat (lacosamide) Now Approved by FDA for Primary Generalized Tonic-Clonic Seizures and Expanded Pediatric Use for People Living with Epilepsy

ATLANTA, Nov. 17, 2020 /PRNewswire/ — UCB, a global pharmaceutical company, today announced th...
read more
Number, Proportion of Pediatric COVID-19 Cases Rising in the U.S.

Number, Proportion of Pediatric COVID-19 Cases Rising in the U.S.

THURSDAY, Oct. 1, 2020 — Pediatric COVID-19 ...
read more
High antiviral antibody levels may herald pediatric COVID-19 complication

High antiviral antibody levels may herald pediatric COVID-19 complication

Measuring blood antibody levels against SARS-CoV-2...
read more
Study shows uptick in at-home pediatric fractures during COVID-19 pandemic

Study shows uptick in at-home pediatric fractures during COVID-19 pandemic

COVID-19 social distancing measures, including the...
read more
Recommendations issued for pediatric abuse-related head trauma

Recommendations issued for pediatric abuse-related head trauma

(HealthDay)—In an American Academy of Pediatrics...
read more
Study examines why colon cancer is more deadly in pediatric and young adult patients

Study examines why colon cancer is more deadly in pediatric and young adult patients

Colon cancer is more likely to be lethal in childr...
read more
BRAF inhibitor shows promising results in pediatric patients with low-grade glioma

BRAF inhibitor shows promising results in pediatric patients with low-grade glioma

Dabrafenib (Tafinlar), a BRAF inhibitor approved t...
read more